iSpecimen Acquires Foldlab AI Products for $4.5 Million
Key Facts
iSpecimen said it completed its acquisition of artificial intelligence products from Foldlab AI on November 2, 2026, in a deal valued at $4.5 million, according to the company’s filing with the U.S. Securities and Exchange Commission. The assets include an agent for discovering disease-associated proteins and a model for predicting and monitoring disease trends, along with related software, models, data rights and intellectual property. The deal expands the role of the company, which operates a biospecimen network, into AI-powered disease intelligence tools. Chief Executive Shaheen Behroozian said combining the network and tools could help researchers identify promising protein targets and better understand disease trends. The company describes this as a potential capability, while part of the consideration depends on meeting product delivery and acceptance conditions.
The purchase price consists of $750,000 paid in cash at closing, stock consideration valued at $2.5 million, and two milestone payments of $625,000 each. The two payments become due only after each product is delivered, tested and accepted under objective criteria. The filing says partial performance or incomplete delivery does not entitle Foldlab to a payment. A payment also will not be made if testing fails or a material defect remains unresolved. As a result, part of the deal’s value is tied to completing product acceptance milestones, rather than simply transferring the assets.
On November 5, iSpecimen issued Foldlab 2,907,977 shares of common stock as partial consideration for the assets. The number of shares was calculated using a volume-weighted average price of $0.8597 per share over the 10 trading days from October 19 to 30, 2026. The issued shares represent about 53.6% of outstanding common shares under the disclosure’s calculation, which is based on 2,518,590 shares outstanding on August 12, 2026, before adding the consideration shares. On that calculation basis, the issuance gives Foldlab a large stake in the share base. The figure does not mean the percentage is calculated against the number of shares outstanding on the issuance date; the filing specifies the date used as the basis.
The consideration shares are subject to a five-year trading restriction from the closing date, with no leakage of shares, and were issued in restricted book-entry form. However, Foldlab retains the right to vote the shares in elections for members of the board of directors. Foldlab granted the company an irrevocable proxy to vote on specified matters related to the deal, while retaining its right to vote on other matters, including board elections. iSpecimen disclosed that there was no change in the composition of the board or executive management upon completion of the deal. These terms distinguish share ownership and trading restrictions from the voting rights retained by the seller.
The deal comes as the latest half-year results included in the financial filing showed the company’s revenue falling to $307,949 in the first half of 2026, from $1,770,645 in the same period of 2025, a decline of 83%. In the second quarter alone, revenue was $151,940, compared with $713,135 in the second quarter of 2025, a drop of 79%. Cash and cash equivalents totaled $4,414,364 on June 30, 2026, compared with $6,880,835 on December 31, 2025. Management said in its financial report that substantial doubt existed about the company’s ability to continue as a going concern and that its plans to address the doubt could not be considered likely to succeed. The financial disclosure places the deal in the context of a company facing a sharp contraction in revenue and a declining cash balance.
In the stock market, iSpecimen shares, listed under the ticker ISPC, closed at $0.843 on November 4, 2026, according to EL7 data. The closing price preceded the share issuance disclosed on November 5, and the data available here do not include a later share-price reading tied to the filing. The original asset purchase agreement was signed on September 4, 2026, before the agreement was amended and the deal closed on November 2. The next step related to the consideration is the delivery, testing and acceptance of each product under the specified objective criteria, for either of the two milestone payments to become due. The information provided did not specify a date for these milestones.